Thinking of joining a study?

Register your interest

Become a volunteer?

NCT03128866 | RECRUITING | Pelvic Mass

Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery
Sponsor:

M.D. Anderson Cancer Center

Brief Summary:

This early phase I trial studies how well tranexamic acid works in reducing the loss of blood in patients with pelvic tumors undergoing hemipelvectomy surgery. Tranexamic acid decreases blood loss by stabilizing clots and preventing clot lysis in patients undergoing surgery.

Condition or disease

Pelvic Mass

Intervention/treatment

Hemipelvectomy

Tranexamic Acid

Phase

EARLY_PHASE1

Detailed Description:

PRIMARY OBJECTIVES: I. To determine if the use of tranexamic acid results in a significant reduction in intraoperative and perioperative blood loss. SECONDARY OBJECTIVES: I. To determine if use of tranexamic acid lowers the amount of blood products transfused in hemipelvectomy surgeries and during first postoperative week. II. To determine if the use of tranexamic acid has an effect on laboratory (lab) measurements preoperatively through postoperative day 7. III. To determine if use of tranexamic acid has an effect on complication, length of intensive care unit (ICU), and hospital stays. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I (TRANEXAMIC ACID): Patients receive tranexamic acid intravenously (IV) over 15 minutes 30 minutes prior to surgery and continuously during hemipelvectomy procedure in the absence of disease progression or unacceptable toxicity. ARM II (NO TRANEXAMIC ACID): Patients undergo standard of care hemipelvectomy in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed up at 7 days.

Study Type : INTERVENTIONAL
Estimated Enrollment : 80 participants
Masking : NONE
Primary Purpose : SUPPORTIVE_CARE
Official Title : Reducing Blood Loss in Hemipelvectomy Surgery With the Use Tranexamic Acid (TXA)
Actual Study Start Date : 2017-05-19
Estimated Primary Completion Date : 2026-05-31
Estimated Study Completion Date : 2026-05-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * Both pediatric and adult patients can be eligible to participate
  • * Cognitively impaired and non-English speakers can be eligible to participate.
  • * Both male and female patients must have a pelvic tumor and are scheduled to have surgery at University of Texas (UT) Monroe Dunaway (MD) Anderson Cancer center that require hemipelvectomy, resulting in pelvic ring disruption
Exclusion Criteria
  • * Patient with a history of genetic prothrombotic state
  • * Patient with a history of thromboembolic disease to include pulmonary embolus or other extremity deep venous thrombosis
  • * Patients with thrombosis of the planned site of resection will not be excluded if the thrombus is caused directly by tumor burden or outflow obstruction
  • * Female patients will not be eligible for this study if she is either pregnant or nursing at the time of enrollment
  • * Patients will not be eligible if they have a history of color vision defects
  • * Patients will not be eligible if they have a history of retinal vein or artery occlusion
  • * Patients will not be eligible if they have a history of intracranial hemorrhage in past 6 months
  • * Patients will not be eligible if they have a history of hypersensitivity to tranexamic acid
  • * Patients will not be eligible if they present with moderate to severe decrease in creatinine clearance (estimated glomerular filtration rate \[eGFR\] \< 45 mL/min/1.73m2)
  • * Patients will not be eligible if they present or have a history of seizure disorder
Tranexamic Acid in Reducing Blood Loss in Patients With Pelvic Tumors Undergoing Hemipelvectomy Surgery

Location Details

NCT03128866

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, Texas

M D Anderson Cancer Center

Houston, Texas, United States, 77030